Gujarat Themis Biosyn Q1 FY27: Revenue up 22.1% to ₹43.8 Cr, PAT up 22.1% to ₹11.1 Cr
Gujarat Themis Biosyn reported Q1 FY27 revenue of ₹43.8 Cr, up 22.1% YoY. PAT grew 22.1% to ₹11.1 Cr, with EPS at ₹1.02. The company is progressing with acquisitions of Sanofi brands and MicroBiopharm Japan, and also investing in new R&D, API, and fermentation facilities in India, alongside a hybrid power plant.
The announcement includes significant financial performance improvements, details on major strategic acquisitions (Sanofi brands, MicroBiopharm Japan), and substantial capex plans, all of which are material to investors.
The company reported strong year-on-year growth in revenue and profit, alongside positive commentary from the Managing Director regarding strategic acquisitions and ongoing infrastructure development, indicating a positive outlook.
Gujarat Themis Biosyn Limited (GTBL) has released its investor presentation for the quarter ended June 30, 2026 (Q1 FY27). The company reported a strong start to the financial year, with healthy sales volumes and improved margins.
Dr. Sachin Patel, Managing Director, highlighted the company's growth momentum, driven by robust sales and stable market demand. He emphasized the strategic significance of recent inorganic expansion initiatives, including the acquisition of Sanofi's brands, which are expected to provide access to new distribution networks in overseas markets, and the acquisition of MicroBiopharm in Japan, which strengthens manufacturing capabilities and product offerings. These moves are aimed at broadening therapy areas and geographical reach, aligning with GTBL's evolution as a global CDMO player.
The company also provided an update on its capex in India, with the new R&D and API units operational and the new fermentation facility development complete. A hybrid power plant in Gujarat is also underway, intended for captive consumption to reduce power costs, grid dependence, and carbon footprint.
Financially, for Q1 FY27, GTBL's top line grew 22.1% year-on-year to ₹43.8 crores. EBITDA increased by 49.4% to ₹20.8 crores, and Profit After Tax (PAT) improved by 22.1% to ₹11.1 crores. The EPS for the quarter stood at ₹1.02. The company also provided annual figures, with FY26 revenue at ₹165.82 crores and PAT at ₹46.68 crores. The balance sheet as of March 31, 2026, shows total equity and liabilities of ₹503.43 crores and total assets of ₹503.43 crores.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.